Profile data is unavailable for this security.
About the company
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
- Revenue in USD (TTM)15.24m
- Net income in USD-25.10m
- Incorporated2011
- Employees13.00
- LocationXOMA Royalty Corp2200 Powell Street, Suite 310EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 204-7239
- Fax+1 (302) 655-5049
- Websitehttps://www.xoma.com/
Mergers & acquisitions
Acquired company | XOMA:NMQ since announced | Transaction value |
---|---|---|
Kinnate Biopharma Inc | 39.63% | 99.33m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rezolute Inc | 0.00 | -68.46m | 323.32m | 59.00 | -- | 2.46 | -- | -- | -1.33 | -1.33 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -53.39 | -50.36 | -56.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
Aldeyra Therapeutics Inc | 0.00 | -37.87m | 328.01m | 10.00 | -- | 3.34 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -50.53m | 330.10m | 57.00 | -- | 1.26 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Codexis Inc | 64.45m | -62.09m | 332.02m | 174.00 | -- | 4.52 | -- | 5.15 | -0.878 | -0.878 | 0.9149 | 0.902 | 0.4259 | 7.03 | 3.62 | 370,379.30 | -41.03 | -17.13 | -54.21 | -20.23 | 75.96 | 77.29 | -96.35 | -37.04 | 3.15 | -- | 0.2806 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
iTeos Therapeutics Inc | 35.00m | -108.14m | 338.56m | 157.00 | -- | 0.51 | -- | 9.67 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
enGene Holdings Inc | 0.00 | -123.44m | 349.30m | 33.00 | -- | 1.52 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Lyell Immunopharma Inc | 54.00k | -210.26m | 358.79m | 224.00 | -- | 0.5512 | -- | 6,644.33 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Sutro Biopharma Inc | 169.36m | -124.45m | 359.00m | 304.00 | -- | 2.36 | -- | 2.12 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
XOMA Royalty Corp | 15.24m | -25.10m | 362.49m | 13.00 | -- | 3.61 | -- | 23.79 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
Jasper Therapeutics Inc | 0.00 | -62.44m | 370.53m | 45.00 | -- | 3.69 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Compass Pathways PLC (ADR) | 0.00 | -144.32m | 372.89m | 186.00 | -- | 1.93 | -- | -- | -2.19 | -2.19 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -52.83 | -40.85 | -57.18 | -44.48 | -- | -- | -- | -- | -- | -- | 0.1337 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 380.59m | 25.00 | -- | -- | -- | 231.36 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
SAGE Therapeutics Inc | 106.40m | -337.59m | 386.00m | 487.00 | -- | 0.6995 | -- | 3.63 | -5.58 | -5.58 | 1.76 | 9.02 | 0.1354 | -- | 5.24 | 218,478.40 | -42.95 | -21.88 | -48.97 | -23.30 | 91.75 | 99.63 | -317.29 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Voyager Therapeutics Inc | 143.77m | 9.02m | 388.82m | 162.00 | 46.47 | 1.16 | 27.99 | 2.70 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
ProQR Therapeutics NV | 20.05m | -23.09m | 399.26m | 157.00 | -- | 9.02 | -- | 19.91 | -0.2839 | -0.2839 | 0.2464 | 0.418 | 0.1406 | -- | -- | 127,701.20 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 30 Jun 2024 | 3.63m | 31.05% |
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 1.10m | 9.36% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 470.36k | 4.02% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 402.79k | 3.44% |
Stonepine Capital Management LLCas of 30 Jun 2024 | 250.13k | 2.14% |
Opaleye Management, Inc.as of 30 Jun 2024 | 250.00k | 2.14% |
Geode Capital Management LLCas of 30 Jun 2024 | 181.60k | 1.55% |
Morgan Stanley Investment Management, Inc.as of 30 Jun 2024 | 157.22k | 1.34% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 141.10k | 1.21% |
TLS Advisors LLCas of 30 Jun 2024 | 120.37k | 1.03% |